OPKO Health, Inc. Aktie News

MIAMI, May 15, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (Nasdaq: OPK) announced today that management will be participating in two investor conferences over the coming weeks. H.C. Wainwright 3 rd Annual BioConnect Investor Conference at Nasdaq, May 20 in New York City.

OPKO Health, Inc. (NASDAQ:OPK ) Q1 2025 Earnings Conference Call April 30, 2025 4:30 PM ET Company Participants Yvonne Briggs - Alliance Advisors IR Dr. Phillip Frost - Chairman and CEO Dr. Elias Zerhouni - Vice Chairman and President Adam Logal - Chief Financial Officer Gary Nabel - Chief Innovation Officer Conference Call Participants Maury Raycroft - Jefferies Yi Chen - H. C. Wainwright & Co...

MIAMI, April 04, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) today announced that its Board of Directors has authorized an increase of $100 million to the Company's existing common stock repurchase program, bringing the aggregate capacity of the program to $200 million. Approximately $41 million of OPKO's common stock has been repurchased under the existing program since its author...

OPKO Health and Entera Bio are partnering to develop a once-daily pill for patients with obesity and other disorders, the companies said on Monday.

Transaction to extend Labcorp's leadership in oncology and expand access to the company's high-quality clinical laboratory services BURLINGTON, N.C. and MIAMI , March 11, 2025 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, and OPKO Health, Inc. (Nasdaq: OPK), a multinational biopharmaceutical and diagnostics company, announced today that...

OPKO Health, Inc. (NASDAQ:OPK ) Q4 2024 Earnings Conference Call February 27, 2025 4:30 PM ET Company Participants Yvonne Briggs - Alliance Advisors IR Dr. Phillip Frost - Chairman and CEO Dr. Elias Zerhouni - Vice Chairman and President Adam Logal - Chief Financial Officer Gary Nabel - Chief Innovation Officer Conference Call Participants Maury Raycroft - Jefferies Jeffrey Cohen - Ladenburg Th...

MIAMI, Feb. 27, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) reports business highlights and financial results for the three and 12 months ended December 31, 2024. Highlights from the fourth quarter of 2024 and recent weeks include the following: Enrollment and dosing underway by Merck in the Phase 1 Epstein-Barr virus (EBV) vaccine trial.

MIAMI, Jan. 09, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (Nasdaq: OPK) announced today that management will be participating in the 43r d Annual J.P. Morgan Healthcare Conference, being held January 13-16, 2025 at Westin St. Francis hotel in San Francisco. Management will be hosting one-on-one meetings with investors and will be presenting on Wednesday, January 15th at 3:00 p.m. Pacific time.